KR101958454B1 - Composition for blocking AGEs production and promoting AGEs decomposition comprising defatted Torreya nucifera's seed extract - Google Patents
Composition for blocking AGEs production and promoting AGEs decomposition comprising defatted Torreya nucifera's seed extract Download PDFInfo
- Publication number
- KR101958454B1 KR101958454B1 KR1020170115269A KR20170115269A KR101958454B1 KR 101958454 B1 KR101958454 B1 KR 101958454B1 KR 1020170115269 A KR1020170115269 A KR 1020170115269A KR 20170115269 A KR20170115269 A KR 20170115269A KR 101958454 B1 KR101958454 B1 KR 101958454B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- ages
- composition
- defatted
- disease
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 87
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 244000111306 Torreya nucifera Species 0.000 title claims abstract description 13
- 235000006732 Torreya nucifera Nutrition 0.000 title claims abstract description 13
- 238000000354 decomposition reaction Methods 0.000 title claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 title abstract description 12
- 230000001737 promoting effect Effects 0.000 title description 5
- 230000000903 blocking effect Effects 0.000 title 1
- 230000009759 skin aging Effects 0.000 claims abstract description 20
- 208000002249 Diabetes Complications Diseases 0.000 claims abstract description 17
- 206010012655 Diabetic complications Diseases 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 15
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 12
- 208000001647 Renal Insufficiency Diseases 0.000 claims abstract description 11
- 201000006370 kidney failure Diseases 0.000 claims abstract description 11
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 10
- 230000005764 inhibitory process Effects 0.000 claims abstract description 9
- 230000036252 glycation Effects 0.000 claims description 28
- 239000000047 product Substances 0.000 claims description 23
- 239000002537 cosmetic Substances 0.000 claims description 19
- 239000007795 chemical reaction product Substances 0.000 claims description 18
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 11
- 230000032683 aging Effects 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 238000006206 glycosylation reaction Methods 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 8
- 230000013595 glycosylation Effects 0.000 claims description 8
- 244000184734 Pyrus japonica Species 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 230000015556 catabolic process Effects 0.000 claims description 6
- 238000006731 degradation reaction Methods 0.000 claims description 6
- 230000001668 ameliorated effect Effects 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 102000008186 Collagen Human genes 0.000 abstract description 20
- 108010035532 Collagen Proteins 0.000 abstract description 20
- 229920001436 collagen Polymers 0.000 abstract description 20
- 238000004132 cross linking Methods 0.000 abstract description 19
- 108010005094 Advanced Glycation End Products Proteins 0.000 abstract description 12
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 10
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 10
- 238000003776 cleavage reaction Methods 0.000 abstract description 10
- 230000007017 scission Effects 0.000 abstract description 10
- 238000009825 accumulation Methods 0.000 abstract description 3
- 101150037717 Mavs gene Proteins 0.000 description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- -1 alerts Substances 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000011785 micronutrient Substances 0.000 description 5
- 235000013369 micronutrients Nutrition 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- 239000002023 wood Substances 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 229920000297 Rayon Polymers 0.000 description 3
- MKOMESMZHZNBIZ-UHFFFAOYSA-M alagebrium Chemical compound [Cl-].CC1=C(C)SC=[N+]1CC(=O)C1=CC=CC=C1 MKOMESMZHZNBIZ-UHFFFAOYSA-M 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 2
- 239000000305 astragalus gummifer gum Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 102000014824 Crystallins Human genes 0.000 description 1
- 108010064003 Crystallins Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 241000488908 Torreya Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000004566 building material Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000451 gelidium spp. gum Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Botany (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 비자나무 유박 추출물(defatted Torreya nucifera's seed extract) 추출물을 유효성분으로 함유하는 최종당화산물 (AGEs, Advanced glycation end-products) 생성 억제 및 분해 촉진용 조성물에 관한 것으로, 보다 구체적으로는 비자나무 유박 추출물을 포함하는 최종당화산물의 생성 억제 및 최종당화산물과 콜라겐 사이의 교차결합 절단에 의한 당뇨합병증, 동맥경화, 신부전증, 류마티스성 관절염, 또는 알츠하이머의 예방 또는 치료용 조성물 또는 피부 노화 억제 및 개선용 조성물에 관한 것이다. The present invention relates to a method for producing defatted Torreya The present invention relates to a composition for inhibiting the formation of advanced glycation end-products (AGEs) containing nucifera seed extract as an active ingredient and more particularly to a composition for promoting the production of a final glycation product A composition for preventing or treating diabetic complications, arteriosclerosis, renal failure, rheumatoid arthritis, or Alzheimer caused by cross-linking cleavage between a final glycated product and collagen, or a composition for inhibiting and improving skin aging.
당화반응(Maillard reaction, Glycation)이란 환원당의 카르보닐기(carbonyl)와 단백질의 유리 아미노기(amino)인 라이신(lysine) 또는 아르기닌(arginine)의 비효소적 반응에 의해 초기 단계의 산물인 쉬프염기(shiff base)를 형성하고, 계속적으로 축합, 재전위, 산화, 분열, 고리화 등의 일련의 복잡한 반응을 통해서 갈색의 비가역적 최종당화산물(Advanced glycation end-products, AGEs)을 형성하는 과정이다.The Maillard reaction (Glycation) is the reaction of an initial stage product, a shiff base, by the nonenzymatic reaction of the carbonyl of the reducing sugar with the free amino of the protein, lysine or arginine, ) And forming brown irreversible final glycation end-products (AGEs) through a series of complex reactions such as condensation, re-dislocation, oxidation, cleavage, and cyclization.
이러한 비가역적 반응산물인 최종당화산물은 일단 생성이 되면 분해되지 않고, 수정체 단백질, 콜라겐(Collagen) 등과 교차결합(Crosslinking)하여 피부나 조직에 축적되고 그 구조와 기능을 비정상적으로 변화시킴으로써 다양한 질환에 관여하는 것으로 알려져 있다. 특히, 당뇨합병증, 동맥경화, 말기 신부전증, 류마티스성 관절염, 알츠하이머, 피부주름형성 등 노화와 관련된 다양한 질환의 진행과정에 최종당화산물이 밀접하게 연관되어 있다는 것이 이미 많은 연구에서 보고되어 왔다(Semin Nephrol. 2007 Mar;27(2):130-43; 및 Curr Alzheimer Res. 2004 Feb;1(1):39-46) This unreversible reaction product, a final glycation product, is not degraded once it is formed, but is cross-linked with lens protein, collagen, etc., accumulated in the skin or tissue, and abnormally changes its structure and function, It is known to be involved. In particular, many studies have reported that end glycated products are closely related to the progress of various diseases associated with aging such as diabetic complications, arteriosclerosis, end stage renal failure, rheumatoid arthritis, Alzheimer's, skin wrinkle formation (Semin Nephrol 2007 Mar; 27 (2): 130-43; and Curr Alzheimer Res. 2004 Feb; 1 (1): 39-46)
그 중 당뇨합병증은 최종당화산물과 연관된 대표적인 질환으로 잘 알려져 있다. 당뇨병이란 체내 인슐린(insulin) 분비와 활성에 장애가 생긴 상태를 특징으로 하는 대표적인 만성질환으로, 8~12시간 금식 후 측정한 혈당이 126 mg/dL 이상이거나 경구 당 부하 검사에서 포도당 섭취 2시간 후 혈당이 200 mg/dL 이상으로 측정되면 당뇨병으로 진단되며, 당뇨병의 가장 고 위험군은 고혈당으로 인한 합병증이다.Among them, diabetic complications are well known as a representative disease associated with the final glycation end product. Diabetes mellitus is a typical chronic disorder characterized by insulin secretion and activity in the body. It is a chronic disease with a blood glucose level of 126 mg / dL or more after 8 to 12 hours of fasting, or 2 hours after glucose intake Is diagnosed as diabetes mellitus when measured at 200 mg / dL or more, and the highest risk of diabetes mellitus is complication due to hyperglycemia.
당뇨합병증을 촉진시키는 요인 중 하나는 당과 혈관 벽의 단백질 또는 지질과 단백질 간의 비효소적 교차결합 반응이다. 보통 정상적인 혈관 내 콜라겐의 교차결합은 N-과 C-말단의 특정 부위에서만 일어나지만 최종당화산물에 의한 콜라겐과의 교차결합은 모든 부위에서 무작위로 일어나면서 비정상적인 교차결합을 형성한다. 이러한 비정상적인 교차결합은 일단 생성이 되면 정상적으로 혈당이 회복되었음에도 불구하고 분해되지 않고, 단백질 생존기간 동안 조직에 축적되어 신경혈관성 장애의 병인으로 작용하여 당뇨성 망막변증, 당뇨성 백내장, 당뇨성 신장병 등의 치명적인 만성 당뇨 합병증을 유발한다.One of the factors promoting diabetic complications is the nonenzymatic cross-linking of proteins or lipids and proteins in the sugar and blood vessel walls. Normally normal cross-linking of intravascular collagen occurs only at specific sites of the N- and C-termini, but cross-linking with collagen by the final glycosylation occurs randomly at all sites and forms abnormal cross-linking. These abnormal cross-linkages, once formed, are not degraded in spite of normal recovery of blood glucose, accumulate in tissues during protein survival and act as a pathogen of neurovascular dysfunction, leading to diabetic retinopathy, diabetic cataract, diabetic nephropathy Causes fatal chronic diabetic complications.
또한, 최종당화산물은 알츠하이머 발병과 연관되어 있다는 연구도 보고되고 있다. 알츠하이머(Alzheimer's disease, AD)는 뇌의 질환으로 인해 생기는 하나의 증후군으로, 대개 만성적이고 진행성으로 나타나며 기억력, 사고력, 학습능력, 언어 및 판단력 등을 포함하는 뇌기능의 다발성 장애를 의미한다.Studies have also been reported that the final glycation end product is associated with Alzheimer's outbreak. Alzheimer's disease (AD) is a syndrome caused by brain disease, usually chronic and progressive, and refers to a multiple disorder of brain function, including memory, thinking, learning, language, and judgment.
알츠하이머의 발병 원인은 정확하게 규명되지는 않았지만 노화와 밀접한 관계가 있으며, 주된 원인으로 베타아밀로이드(β-amyloid)라는 단백질이 뇌에 축적되어 엉킴(Aggregation)으로써 발병되는 것으로 추측되고 있다. 이전 연구에 따르면, 정상적인 생리 조건하에서 베타아밀로이드는 서서히 응집되는 반면 최종당화산물과의 교차결합에 의해 변형된 베타아밀로이드(AGE-modified β-amyloid)는 급속하게 응집되는 것으로 보고되어 있다(Neurobiology, 91, 4766-4770, 1994).The cause of Alzheimer's disease is not precisely known, but it is closely related to aging. It is presumed that the main cause is the accumulation of β-amyloid protein in the brain and aggregation. Previous studies have shown that, under normal physiological conditions, beta amyloid aggregates slowly, while AGE-modified beta-amyloid is rapidly aggregated by cross-linking with the final glycation end product (Neurobiology, 91 , 4766-4770,1994).
또한, 최종당화산물과 콜라겐의 비정상적인 교차결합은 피부 노화와 밀접한 관련이 있다. 피부 노화는 크게 내인성 노화와 외인성 노화로 분류될 수 있다. 내인성 노화는 나이가 들어감에 따라 발생하는 자연적인 노화 현상이며, 유전자 등에 의해 영향을 받고, 외인성 노화는 자외선, 흡연, 환경오염 등과 같은 외부적인 요인에 의해 발생하는 노화 현상으로 자외선이 가장 큰 원인이 되기 때문에 광노화라고도 알려져 있다.In addition, abnormal cross-linking of the final glycation end product with collagen is closely related to skin aging. Skin aging can be broadly classified into endogenous aging and extrinsic aging. Endogenous aging is a natural aging phenomenon caused by aging. It is affected by genes. Exogenous aging is an aging phenomenon caused by external factors such as ultraviolet rays, smoking and environmental pollution. It is also known as photoaging.
피부 노화의 주된 외관적인 변화는 진피의 구조적인 변화에 의한 주름형성과 피부탄력의 저하이다. 콜라겐은 피부 진피층 90%를 구성하는 물질이며 피부의 탄력을 부여하는 주요 성분으로, 피부 주름은 이런 콜라겐의 구조가 무너지면서 발생한다. 비교적 반감기가 긴 콜라겐은 쉽게 당화반응이 발생하고 최종당화산물과 콜라겐의 교차결합이 일어나면서 피부의 탄력이 감소되고 주름이 형성되어 피부 노화를 촉진시킨다. 이전 연구에 따르면 최종당화산물이 증가된 농도로 존재시 랫드(Rats)의 콜라겐 미세섬유에서 비정상적인 구조적 변화가 관찰되었다는 것이 밝혀진 바가 있다 (Odetti P, Aragno I, et al. Gerontology, 1998, 44(4); 187-91). 또 다른 피부 노화의 외관적인 변화는 노인성 반점이다. 노인성 반점은 피부 노화로 인해 형성되는 피부 상의 검버섯으로, 다양한 요인에 의해 발생하는 것으로 알려져 있으며 그 중 최종당화산물의 축적과도 밀접한 관련이 있는 것으로 알려져 있다.The main appearance change of skin aging is wrinkle formation due to structural change of dermis and decrease of skin elasticity. Collagen is a substance that constitutes 90% of the skin's dermis and is the main ingredient that gives skin elasticity. Skin wrinkles occur when collagen structure collapses. Collagen with a relatively long half-life easily undergoes glycosylation reaction and cross-linking of collagen with final glycosylated product causes skin elasticity to be reduced and wrinkle to promote skin aging. Previous studies have shown that abnormal structural changes were observed in the collagen microfilaments of rats when the final glycosylated product was present at increased concentrations (Odetti P, Aragno I, et al. Gerontology, 1998, 44 (4 ); 187-91). Another change in the appearance of aging skin is senility spots. It is known that senile spots are caused by various factors, and are known to be closely related to the accumulation of final glycation products.
이처럼 최종당화산물은 다양한 질환에 연관되어 있으며, 이에 따라 우리나라를 비롯한 많은 선진국들이 최종당화산물 생성을 저해하거나 이미 형성된 최종당화산물 교차결합을 분해할 수 있는 소재의 연구개발에 집중적으로 투자하고 있다. 특히, 최근에는 부작용을 최소화 시킬 수 있는 안전한 소재에 대한 관심이 높아지면서 천연물을 기반으로 하는 소재 개발의 중요성이 매우 높아지고 있다.As such, the final glycation products are associated with various diseases. Therefore, many advanced countries including Korea are investing heavily in the research and development of materials capable of inhibiting the final glycation end products or decomposing the final glycation end products. In particular, as interest in safe materials that can minimize side effects has increased recently, development of materials based on natural materials is becoming very important.
비자나무(Torreya nucifera)는 겉씨식물 구과목 주목과의 상록교목으로서 우리나라 남부와 제주도에 나는 상록수이다. 전 세계적으로 우리나라와 일본에만 제한되어 분포하며, 토심이 깊고 비옥한 사질양토에서 잘 자란다. 비자나무는 예로부터 목재가 탄력이 좋아 건축재, 가구재, 조각재 등 관상용과 공업용으로 많이 쓰였고, 한방과 민간에서는 과실을 구충, 발모, 건위, 조경, 장출혈 등에 약재로 사용되어 왔으며, 종자는 먹거나 기름을 짜내서 이용되었다. Visible wood ( Torreya nucifera ) is an evergreen tree with a focus on gymnosperm, and is an evergreen tree in southern Korea and Jeju Island. It is distributed all over the world only in Korea and Japan, and it grows well in deep and fertile sandy loam. Visa trees have been widely used for ornamental and industrial purposes such as building materials, furniture and sculptures because of their good resilience of timber, and in oriental and private sectors, fruits have been used as medicines for insect repellent, hair growth, Was used.
이러한 비자나무 잎, 열매, 종자의 효능과 관련하여 대한민국 등록특허 10-1155714호 비자나무의 미성숙 열매 또는 종자 추출물을 함유하는 화장료 조성물, 대한민국 등록특허 10-1002012호 산딸나무, 찔레나무, 비자나무, 파초 및 죽절초 혼합물의 추출물을 함유하는 화장료 조성물, 대한민국 등록특허 10-0552269호 금등화 추출물 또는 비자 추출물로부터 선택된 1종 이상을 주요 활성성분으로 함유하는 피부외용 화장료 조성물, 대한민국 등록특허 10-1434449호 비자나무 잎 정유 추출물을 이용한 항스트레스성 천연 향료 조성물 등이 있다. Regarding the efficacy of such visa tree leaves, fruits and seeds, Korean Patent Registration No. 10-1155714 discloses a cosmetic composition containing an immature fruit or seed extract of Viza wood, Korean Patent No. 10-1202012, a berry tree, a briarwood, A cosmetic composition containing an extract of Bacillus subtilis and Bacillus subtilis extract, a Korean Patent Registration No. 10-0552269, and a cosmetic composition for external use containing at least one member selected from a quartz extract or a visa extract as a main active ingredient, Korean Patent No. 10-1434449 And an anti-stress natural perfume composition using an essential oil extract of visa tree leaf.
그러나 상기 특허 문헌을 포함하여 현재까지 비자나무 유박의 당뇨합병증, 알츠하이머 및 피부노화 예방 또는 치료 효능에 관해서는 전혀 보고된 바가 없다.However, there have been no reports on the diabetic complications, Alzheimer's and skin aging prevention or treatment efficacy of visa wood oil including the patent documents.
이에 본 발명자들은 비자나무 유박 추출물의 최종당화산물 생성 저해 및 최종당화산물 교차결합 절단 효능을 확인하고, 상기 추출물이 당뇨합병증, 알츠하이머 등의 최종당화산물 관련 질환 및 피부 노화 예방 또는 치료용 용도로 사용 될 수 있음을 확인함으로써 본 발명을 완성하게 되었다.Accordingly, the inventors of the present invention confirmed the inhibition of ultimate glycosylation and the ultimate glycosylated product cross-linking cleavage activity of visa wood oil extract, and the extracts were used for diabetic complications, diseases associated with ultimate glycosylation such as Alzheimer's, The present invention has been completed.
따라서, 본 발명에서 해결하고자 하는 기술적 과제는 비자나무 유박 추출물（defatted Torreya nucifera's seed extract)을 포함하는 최종당화산물 생성 억제 및 분해를 촉진과 관련된 질환을 예방 또는 치료하기 위한 약학적 조성물을 제공하기 위한 것이다.Accordingly, a technical problem to be solved by the present invention is to provide a pharmaceutical composition for preventing or treating a disease associated with inhibition of formation of final glycation end products and promotion of degradation, including defatted Torreya nucifera's seed extract will be.
본 발명에서 해결하고자 하는 다른 기술적 과제는 비자나무 유박 추출물（defatted Torreya nucifera's seed extract)을 포함하는 최종당화산물의 생성을 억제하고 분해를 촉진함으로써 피부 노화를 억제 또는 개선하기 위한 화장품 조성물을 제공하기 위한 것이다.Another object of the present invention is to provide a cosmetic composition for suppressing or improving skin aging by inhibiting the production of a final glycation product including defatted Torreya nucifera's seed extract and accelerating decomposition will be.
본 발명에서 해결하고자 하는 또다른 기술적 과제는 비자나무 유박 추출물（defatted Torreya nucifera's seed extract)을 포함하는 최종당화산물 생성 억제 및 분해를 촉진과 관련된 질환을 예방 또는 개선하기 위한 식품 조성물을 제공하기 위한 것이다.Another technical problem to be solved in the present invention is to provide a food composition for preventing or ameliorating a disease associated with the promotion of the inhibition of the final glycogen production and the degradation including defatted Torreya nucifera's seed extract .
상기한 기술적 과제를 해결하기 위하여, 본 발명에서는 비자나무 유박 추출물（defatted Torreya nucifera's seed extract)을 유효성분으로 포함하는 당뇨합병증, 동맥경화, 신부전증, 류마티스성 관절염 및 알츠하이머로 이루어진 군에서 선택된 하나 이상의 질환의 예방 또는 치료용 약학적 조성물을 제공한다. In order to solve the above-mentioned technical problems, the present invention provides a pharmaceutical composition for treating diseases caused by diabetic complications including defatted Torreya nucifera's seed extract as an active ingredient, arteriosclerosis, renal failure, rheumatoid arthritis and Alzheimer's disease Or a pharmaceutically acceptable salt thereof.
또한, 상기한 다른 기술적 과제를 해결하기 위하여, 본 발명에서는 비자나무 유박 추출물（defatted Torreya nucifera's seed extract)을 유효성분으로 포함하는 피부 노화 예방 또는 개선을 위한 화장료 조성물을 제공한다.Also, in order to solve the above technical problems, the present invention provides a cosmetic composition for prevention or improvement of skin aging comprising as an active ingredient defatted Torreya nucifera's seed extract.
또한, 상기한 또다른 기술적 과제를 해결하기 위하여, 본 발명에서는 비자나무 유박 추출물（defatted Torreya nucifera's seed extract)을을 유효성분으로 포함하는 당뇨합병증, 동맥경화, 신부전증, 류마티스성 관절염 및 알츠하이머로 이루어진 군에서 선택된 하나 이상의 질환 또는 피부 노화 예방 또는 개선용 식품 조성물을 제공한다. In order to solve the above-mentioned other technical problem, the present invention provides a method for treating diabetic complications including arteriosclerosis, renal failure, rheumatoid arthritis and Alzheimer's disease, which comprises the defatted Torreya nucifera's seed extract as an active ingredient ≪ / RTI > or a food composition for preventing or ameliorating skin aging.
본 발명의 최종당화산물 생성 억제 및 분해 촉진용 조성물의 유효성분인 비자나무(Torreya nucifera)는 우리나라 남부와 제주도에 나는 상록수로 유박은 기름을 짜고 남은찌꺼기를 뜻한다．The active ingredient of the composition for suppressing the formation of the final glycation end product and promoting degradation of the present invention is Torinia nucifera , which is an evergreen tree in the southern part of Korea and Jeju Island, and a remnant of oil.
본 발명에 있어서, 비자나무 유박 추출물은 당업계에 공지된 추출방법 및 추출용매를 이용하여 수득할 수 있으며, 바람직하게는 물, 탄소수 1-4의 무수 또는 함수 저급 알코올(메탄올, 에탄올, 프로판올, 부탄올 등), 상기 저급 알코올과 물과의 혼합용매, 아세톤, 에틸 아세테이트, 클로로포름 또는 1,3-부틸렌글리콜을 추출 용매로 하여 수득할 수 있다.In the present invention, the non-viscose oil extract can be obtained by using an extraction method and an extraction solvent known in the art, preferably water, anhydrous or hydrated lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, Butanol, etc.), a mixed solvent of the lower alcohol and water, acetone, ethyl acetate, chloroform or 1,3-butylene glycol as an extraction solvent.
또한, 상기 비자나무 유박 추출물은 상기 추출용매에 의하여 추출하는 방법 외에 통상적인 정제 과정을 거쳐서도 수득할 수 있다. 예를 들어, 일정한 분자량 컷-오프 값을 갖는 한외여과막을 이용한 분리, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획을 통하여도 비자나무 유박 추출물을 수득할 수 있다.In addition, the non-canola oil extract can also be obtained through a conventional purification process in addition to the extraction method using the above-mentioned extraction solvent. For example, separation using an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatographies (made for separation by size, charge, hydrophobicity or affinity) Through the obtained fractions, a non-canola oil extract can also be obtained.
본 발명의 구체적인 하나의 실시양태에 따르면, 비자나무 유박을 음건하여 마쇄한 후 건조된 시료의 중량의 0.5 내지 20배, 바람직하게는 1 내지 15배 분량의 물, 에탄올, 메탄올 등과 같은 C1 내지 C4의 저급 알코올 또는 물과 에탄올이 1:0.1 내지 1:10, 바람직하게는 1:0.2 내지 1:9의 혼합비(㎏/ℓ)로 혼합된 혼합용매를 이용하여 실온에서 약 0.5 내지 48시간, 바람직하게는 1 내지 30시간 동안 교반추출, 열수 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출 등의 추출방법을 사용하여, 바람직하게는 초음파 추출한 후 수득한 추출액을 여과, 감압농축 또는 건조하여 비자나무 유박 추출물을 수득할 수 있다.According to an embodiment the specific one of the present invention, C 1 to, such as Visa tree after grinding to shade the oil cake from 0.5 to 20 times the weight of the dried sample, preferably 1 to 15-fold amount of water, ethanol, methanol, C 4 lower alcohol or water and ethanol at a mixing ratio (kg / l) of 1: 0.1 to 1: 10, preferably 1: 0.2 to 1: 9, at room temperature for about 0.5 to 48 hours , Preferably 1 to 30 hours, using an extraction method such as stirring extraction, hot water extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction, preferably after ultrasonic extraction, is filtered, concentrated under reduced pressure or dried, Wooden berries extract can be obtained.
본 발명에 있어서, 비자나무 유박 추출물은 추출, 분획 또는 정제의 각 단계에서 얻어지는 모든 추출액, 분획 및 정제물, 그들의 희석액, 농축액 또는 건조물을 모두 포함한다.In the present invention, the non-viscose oil extract includes all extracts, fractions and tablets obtained in each step of extraction, fractionation or purification, and diluted solutions, concentrates or dried products thereof.
본 발명의 구체적인 실시양태에 따르면, 비자나무 유박 추출물은 최종당화산물의 생성을 저해하고, 최종당화산물과 콜라겐의 교차결합을 절단하는 효능을 가짐으로써 당뇨합병증, 동맥경화, 신부전증, 류마티스성 관절염, 또는 알츠하이머의 예방 또는 치료효과를 가지며, 피부 노화 억제 및 개선효과를 가진다. According to a specific embodiment of the present invention, the extract of Vijayama japonica inhibits the production of the final glycosylated product and has the effect of cutting off the cross-linking of the collagen with the final glycosylated product, thereby preventing diabetic complications, arteriosclerosis, renal failure, rheumatoid arthritis, Or Alzheimer ' s disease, and has an effect of inhibiting and improving skin aging.
본 발명의 바람직한 하나의 구현예에 따르면, 본 발명은 비자나무 유박 추출물을 유효성분으로 포함하는 당뇨합병증, 동맥경화, 신부전증, 류마티스성 관절염 또는 알츠하이머 예방 또는 치료용 약학적 조성물로서, 상기 질환은 비자나무 유박 추출물에 의한 최종당화산물 생성 억제 및 분해 촉진에 의해 예방 또는 치료되는 것을 특징으로 하는 조성물에 관한 것이다.According to one preferred embodiment of the present invention, the present invention provides a pharmaceutical composition for preventing or treating diabetic complications, arteriosclerosis, renal failure, rheumatoid arthritis or Alzheimer's disease, Wherein the composition is prevented or treated by inhibiting the formation of the final glycation end product by the extract of the tree sapling and accelerating the decomposition.
본 발명의 약학적 조성물은 비자나무 유박 추출물을 전체 조성물에 대하여 0.001 내지 10 중량%, 바람직하게는 0.001 내지 5 중량%을 포함할 수 있다. 상기 함유량이 0.001 중량% 미만인 경우에는 AGEs 생성 억제 및 분해 활성 효과가 너무 미약하고, 10 중량%를 초과하는 경우에는 함량의 증가에 따른 효과의 증가가 미비하여 제형상의 안정성이 확보되지 않는 문제점이 있다. The pharmaceutical composition of the present invention may contain 0.001 to 10% by weight, preferably 0.001 to 5% by weight, based on the whole composition of a visa oil extract. When the content is less than 0.001% by weight, the effect of inhibiting the formation of AGEs and decomposing activity is too weak. When the content is more than 10% by weight, have.
본 발명에 따른 약학적 조성물은 비자나무 유박 추출물 외에 약학적 조성물에 통상적으로 이용되는 성분들을 추가적으로 포함할 수 있다. 예를 들어, 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 및 담체를 포함할 수 있다.The pharmaceutical composition according to the present invention may further include ingredients commonly used in pharmaceutical compositions in addition to the extract of Visa Extract. For example, lubricants, wetting agents, sweeteners, flavoring agents, emulsifying agents, suspending agents, preservatives and carriers.
상기 약학적 조성물로 적합한 담체는 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 들 수 있으나, 이에 한정되는 것은 아니다. 적합한 약학적으로 허용되는 담체 및 제제는, 예를 들어, Remington's Pharmaceutical Sciences (19th ed., 1995)에 상세히 기재되어 있다.Suitable carriers for such pharmaceutical compositions include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, , Syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, but are not limited thereto. Suitable pharmaceutically acceptable carriers and formulations are described in detail, for example, in Remington's Pharmaceutical Sciences (19th ed., 1995).
상기 약학적 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 경구 또는 비경구 투여 등의 다양한 경로로 투여될 수 있으며, 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내경막 또는 뇌혈관내(intracerebroventricular) 주사에 의해 투여될 수 있다.The pharmaceutical composition may be administered by various routes such as oral or parenteral administration to mammals such as rats, mice, livestock, humans, etc., and all manner of administration may be expected, for example, oral, Intravenous, intramuscular, subcutaneous, intrauterine or intracerebroventricular injections.
상기 약학적 조성물은 의학적으로 유효한 양을 투여한다. 본 발명에서 약학적으로 유효한 양은 의학적 치료 또는 예방에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료 또는 예방하기에 충분한 양을 의미하며, 유효 용량 수준은 질환의 종류 및 이의 중증도, 약물의 활성, 환자의 연령, 체중, 건강 및 성별, 환자의 약물에 대한 민감도, 사용된 특정 추출물의 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 사용된 특정 추출물과 배합 또는 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 일반적으로, 성인 기준으로 0.1 내지 1,000mg/kg, 바람직하게는 10 내지 100mg/kg의 용량을, 일일 1회 내지 수회 투여할 수 있다. 또한 외용제인 경우에는 성인 기준으로 1.0 내지 3.0ml의 양으로 1일 1회 내지 5회 도포하여 1개월 이상 계속 하는 것이 좋다. 다만 상기 투여량에 의해 본 발명의 범위를 한정하는 것은 아니다.The pharmaceutical composition is administered in a medically effective amount. In the present invention, a pharmaceutically effective amount means an amount sufficient to treat or prevent a disease at a reasonable benefit / risk ratio applicable to medical treatment or prevention. The effective dose level will depend on the type of disease and its severity, Including the age, weight, health and sex of the patient, sensitivity of the patient to the drug, time of administration of the particular extract used, route of administration and rate of release, duration of treatment, Can be determined according to factors well known in the art. Generally, a dose of 0.1 to 1,000 mg / kg, preferably 10 to 100 mg / kg on an adult basis can be administered once to several times per day. When the composition is an external preparation, it is preferable to apply the composition in an amount of 1.0 to 3.0 ml on an adult basis once to five times a day and continue for 1 month or more. However, the scope of the present invention is not limited by the dose.
상기 약학적 조성물은 당해 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약학적으로 허용되는 담체 및/또는 부형제와 함께 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 치료 목적에 따라 약제학 분야에서 통상적인 제제로 제형화될 수 있는데, 예를 들어, 정제, 캅셀제, 산제, 과립, 현탁제, 유제, 시럽제, 유탁제, 경고제, 연고제, 스프레이제, 오일제, 겔제, 주정제, 틴크제, 욕제, 리니먼트제, 로션제, 패취제, 패드제, 크림제 등으로 제형화될 수 있다. 또한, 환부에 직접 도포하는 국소투여를 목적으로 하는 피부 외용제로서 바람직하게 사용될 수 있는데, 이 경우 연고제, 로션제, 스프레이제, 젤 등의 형태가 바람직하다. 이들 피부 외용제는 또한 치료 부위에 직접 적용될 수 있는 지지 기재(support base) 또는 매트릭스 등에 포함될 수 있으며, 지지기재의 예는 거즈 또는 붕대를 포함한다.The pharmaceutical composition may be prepared in a unit dosage form by formulating it together with a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person skilled in the art to which the present invention belongs. Into a capacity container. The formulations may be formulated into tablets, capsules, powders, granules, suspensions, emulsions, syrups, emulsions, alerts, ointments, sprayers, oils A tablet, a tincture, a bath, a liniment, a lotion, a patch, a pad, a cream, and the like. In addition, it can be preferably used as an external preparation for skin intended for topical administration for application directly to the affected area. In this case, a form such as an ointment, a lotion, a spray or a gel is preferable. These external preparations for skin may also be included in a support base or matrix or the like, which can be applied directly to the treatment site, and examples of the support substrate include gauze or bandages.
본 발명의 바람직한 하나의 구현예에 따르면, 본 발명은 비자나무 유박 추출물을 유효성분으로 포함하는 피부 노화 예방 또는 개선용 화장료 조성물로서, 상기 피부 노화 억제 및 개선은 비자나무 유박 추출물에 의한 최종당화산물 생성 억제 및 분해 촉진에 의해 예방 또는 치료되는 것을 특징으로 하는 조성물에 관한 것이다.According to one preferred embodiment of the present invention, the present invention relates to a cosmetic composition for preventing or improving skin aging comprising an extract of Visa Extract as an active ingredient, wherein the inhibition and improvement of skin aging is a final glycation product Production inhibition and promotion of degradation. ≪ Desc /
상기 비자나무 유박 추출물은 전체 조성물에 대하여 0.001 내지 10 중량%가 바람직하다. 0.0001 중량% 미만인 경우에는 AGEs 생성 억제 및 분해 활성 효과가 너무 미약하고, 10 중량%를 초과하는 경우에는 함량의 증가에 따른 효과의 증가가 미비하여 제형상의 안정성이 확보되지 않는 문제점이 있다. 보다 바람직하게는 비자나무 유박 추출물은 전체 조성물에 대하여 0.001 내지 5 중량%이 포함된다.The non-potato extract preferably is 0.001 to 10% by weight based on the total composition. When the content is less than 0.0001% by weight, the effect of inhibiting the formation of AGEs and the activity of decomposing activity is too weak. When the content is more than 10% by weight, the effect of increasing the content is not increased. More preferably, the non-visbreaking oil extract contains 0.001 to 5% by weight based on the total composition.
본 발명에 따른 화장료 조성물은 비자나무 유박 추출물 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 추가적으로 포함할 수 있다. 예를 들어, 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함될 수 있다. 또한 상기 화장료 조성물은 피부 미백효과를 증진시키기 위하여 피부 흡수 촉진 물질을 추가로 포함할 수 있다.The cosmetic composition according to the present invention may further comprise components commonly used in cosmetic compositions in addition to the extract of Visa Extract. For example, conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavoring agents, and carriers may be included. In addition, the cosmetic composition may further include a skin absorption promoting substance to improve the skin whitening effect.
상기 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징제, 오일, 분말 파운데이션, 유액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 영양 크림, 수렴 화장수, 유연 화장수, 로션, 에센스, 영양젤 또는 마사지 크림의 제형으로 제조될 수 있다.The cosmetic composition may be prepared in any form conventionally produced in the art and may be in the form of, for example, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant- , A powder foundation, an emulsion foundation, a wax foundation, and a spray, but the present invention is not limited thereto. More specifically, it can be prepared as a nutritional cream, a convergent lotion, a soft lotion, a lotion, an essence, a nutritional gel or a massage cream.
상기 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라가칸트검, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the cosmetic composition is a paste, a cream or a gel, the carrier component may be an animal oil, vegetable oil, wax, paraffin, starch, tragacanth gum, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide Can be used.
상기 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있다.When the formulation of the cosmetic composition is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of spray, a mixture of chlorofluorohydrocarbons, Propellants such as propane / butane or dimethyl ether.
상기 화장료 조성물의 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 가용화제 또는 유화제가 이용되고, 예컨대 용매로서 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸렌글리콜, 가용화제 또는 유화제로서 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르 등이 이용될 수 있다.In the case of the solution or emulsion of the cosmetic composition, a solvent, a solubilizer or an emulsifier is used as a carrier component. Examples of the solvent include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, , 3-butylene glycol, a glycerol aliphatic ester, a polyethylene glycol, or a fatty acid ester of sorbitan can be used as a solubilizing agent or an emulsifying agent.
상기 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미결정 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라가칸트검 등이 이용될 수 있다.When the formulation of the cosmetic composition is in the form of a suspension, the carrier component may be a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tragacanth gum may be used.
상기 화장료 조성물의 제형이 계면-활성제 함유 클렌징제인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the cosmetic composition is an interfacial active agent-containing cleansing agent, it is preferable to use, as carrier components, aliphatic alcohol sulfates, aliphatic alcohol ether sulfates, sulfosuccinic acid monoesters, isethionates, imidazolinium derivatives, methyltaurate, sarcosinates, fatty acids Amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester.
본 발명의 바람직한 하나의 구현예에 따르면, 본 발명은 비자나무 유박 추출물을 유효성분으로 포함하는 당뇨합병증, 동맥경화, 신부전증, 류마티스성 관절염, 알츠하이머, 피부 노화 예방 또는 개선용 식품 조성물로서, 상기 질환 및 피부 노화의 억제 및 개선은 비자나무 유박 추출물에 의한 최종당화산물 생성 억제 및 분해 촉진에 의해 예방 또는 개선되는 것을 특징으로 하는 조성물에 관한 것이다. According to one preferred embodiment of the present invention, the present invention provides a food composition for preventing or ameliorating diabetic complications, arteriosclerosis, renal failure, rheumatoid arthritis, Alzheimer's, skin aging, And inhibition and improvement of skin aging are prevented or ameliorated by inhibition of the formation of final glycosylation by the extract of non-viscous wood extract and promotion of degradation.
본 발명의 식품 조성물에는 유효성분으로서 비자나무 유박 추출물뿐만 아니라 식품 제조 시에 통상적으로 첨가되는 성분, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 추가로 포함할 수 있다.The food composition of the present invention may further contain, as an active ingredient, not only an extract of Vijayabi extract, but also components such as proteins, carbohydrates, fats, nutrients, flavoring agents and flavors that are ordinarily added in food production.
상기 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다.Examples of such carbohydrates are monosaccharides, such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings.
예컨대, 본 발명의 식품 조성물이 드링크제로 제조되는 경우에는 본 발명의 비자나무 유박 추출물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액, 감초 추출액 등을 추가로 포함시킬 수 있다.For example, when the food composition of the present invention is prepared as a drink, it additionally contains citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, etc., .
상기 비자나무 유박 추출물은 전체 조성물에 대하여 0.001 내지 10 중량%가 바람직하다. 0.0001 중량% 미만인 경우에는 AGEs 생성 억제 및 분해 활성 효과가 너무 미약하고, 10 중량%를 초과하는 경우에는 함량의 증가에 따른 효과의 증가가 미비하다는 문제점이 있다. The non-potato extract preferably is 0.001 to 10% by weight based on the total composition. When the content is less than 0.0001% by weight, the effect of inhibiting the formation of AGEs and the activity of decomposing activity are too weak. When the content is more than 10% by weight, the effect of increasing the content is insufficient.
본 발명의 하나의 구현예에 따르면, 본 발명은 비자나무 유박 추출물을 포함하는 조성물을 이용하여 당뇨합병증, 동맥경화, 신부전증, 류마티스성 관절염 및 알츠하이머로 이루어진 군에서 선택된 하나 이상의 질환을 예방 또는 치료하는 방법에 관한 것이다.According to one embodiment of the present invention, the present invention provides a method for preventing or treating diabetic complications, arteriosclerosis, renal failure, rheumatoid arthritis, and one or more diseases selected from the group consisting of Alzheimer's disease ≪ / RTI >
본 발명의 하나의 구현예에 따르면, 본 발명은 비자나무 유박 추출물을 포함하는 조성물을 이용하여 피부 노화를 예방 또는 개선하는 방법에 관한 것이다.According to one embodiment of the present invention, the present invention relates to a method for preventing or ameliorating skin aging using a composition comprising a non-visbreaking oil extract.
한편, 본 발명의 비자나무 유박 추출물은 천연물질로서 인체에 무해하며, 독성 및 부작용이 거의 없으므로 장기간 사용시에도 안심하고 사용할 수 있으며, 특히 상기한 바와 같은 약학적, 화장료 및 식품 조성물에 안전하게 적용할 수 있다.On the other hand, the extract of Vijayama japonica extract of the present invention is a natural substance which is harmless to the human body and has little toxicity and side effects, so that it can be safely used even in long-term use and can be safely applied to pharmaceuticals, cosmetics and food compositions as described above have.
이와 같이, 본 발명에 따르면, 비자나무 유박 추출물은 최종당화산물 생성 억제 효과와 최종당화산물과 콜라겐 사이의 교차결합 절단 효과를 통해 AGEs 축적에 따른 당뇨합병증, 동맥경화, 신부전증, 류마티스성 관절염 또는 알츠하이머 등과 같은 최종당화산물 관련 질환 및 피부 노화 예방 또는 개선용 용도로 사용될 수 있다. As described above, according to the present invention, the extract of Vijayama japonica extract has an effect of suppressing the formation of final glycation end products and the cross-linking cleavage effect between the final glycation products and collagen, thereby preventing diabetic complications, arteriosclerosis, renal failure, rheumatoid arthritis or Alzheimer's And the like, and for preventing or ameliorating skin aging.
도 1은 최종당화산물과 콜라겐의 교차결합에 대한 비자나무 유박 추출물의 절단 효능을 비교 평가한 결과를 나타낸 도면이다. FIG. 1 is a graph showing the results of comparative evaluation of the cleavage efficacy of a visa oil extract against cross-linking of collagen with a final glycation end product.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다. Hereinafter, embodiments of the present invention will be described in detail to facilitate understanding of the present invention. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the invention are provided to more fully describe the present invention to those skilled in the art.
<실시예 1> 비자나무 유박 추출물 제조Example 1: Preparation of a visa oil extract
비자유박은 제주산 비자씨를 이용하여 오일을 착유하고 남은 유박을 이용하였다. 상기 원물을 20 내지 35℃에서 음건한 다음, 분쇄하여 입자의 크기가 1mm 이하가 되도록 하였다. 그 후 분쇄된 비자유박 분말 1kg을 70% 에탄올 용매에 담근 후 48시간 초음파 추출한 다음 수득한 추출액을 여과지(Advantes, No.2)를 사용하여 여과하였다. 이어서, 감압 농축하여 비자유박 추출물을 제조하였다.The visa leaves were milked with the visa seeds from Jeju and used the remaining leaves. The raw material was shaved at 20 to 35 DEG C and then pulverized to have a particle size of 1 mm or less. Thereafter, 1 kg of pulverized viscose powder was immersed in a 70% ethanol solvent and sonicated for 48 hours. The obtained extract was filtered using a filter paper (Advantes, No. 2). Subsequently, the extract was concentrated under reduced pressure to prepare a visa oil extract.
<시험예 1> 비자나무 유박 추출물의 최종당화산물 생성 저해 효능 평가 (in vitro)≪ Test Example 1 > Evaluation of inhibitory effect on the final glycation end product of the extract of Vijayama japonica extract ( in vitro )
10 mg/mL 소혈청알부민(Bovine serum albumin, BSA), 10 mM 글리코알데히드(Glycolaldehyde), 1 mM 디에틸렌트리아미노펜타아세티애씨드(DTPA), 0.1 M 인산염완충액(phosphate buffer, pH 7.4), 0.02% 아지드화나트륨(sodium azide)과 상기 실시예 1에서 제조된 비자나무 유박 추출물을 혼합한 반응물을 37℃에서 5일 동안 배양하였으며, 양성대조군으로는 최종당화산물 생성 저해제로 잘 알려진 아미노구아니딘(Aminoguanidine, AG)를 처리하였다. 최종당화산물 형성 정도는 분광형광계를 이용하여 Ex=340nm/Em=430nm에서 측정한 형광값을 하기 수학식 1에 대입하여 계산한다. 그 결과는 하기 표 1에 나타내었다.Bovine serum albumin (BSA), 10 mM glyceraldehyde, 1 mM diethylenetriaminepentaacetic acid (DTPA), 0.1 M phosphate buffer (pH 7.4), 0.02% The mixture of sodium azide and the extract of Viza japonica extract prepared in Example 1 was incubated at 37 ° C for 5 days. As a positive control, aminoguanidine (Aminoguanidine), which is well known as a final glycation endogenesis inhibitor, , AG). The degree of formation of the final glycation end product is calculated by substituting the fluorescence value measured at Ex = 340 nm / Em = 430 nm using the spectrophotometer into the following equation (1). The results are shown in Table 1 below.
(ppm)AG
(ppm)
(ppm)Visa tree extract
(ppm)
(ppm)Visa tree leaves extract
(ppm)
상기 표 1에 기재된 바와 같이, 비자나무 유박 추출물은 농도 의존적인 최종당화산물 저해 효능이 있음을 확인할 수 있었다. 비자나무 추출물 또한 최종당화산물 저해 효능이 있었으나 비자나무 유박 추출물에 비해 그 효능이 낮았다.As shown in the above Table 1, it was confirmed that the extract of Viza japonica extract had a concentration-dependent inhibitory effect on final glycation end products. The visa tree extract also had the effect of inhibiting the final glycosylation, but its efficacy was lower than that of the visa oil extract.
<시험예 2> 최종당화산물과 콜라겐의 교차결합에 대한 비자나무 유박 추출물의 절단 효능 평가 (in vitro)≪ Test Example 2 > Evaluation of the cleavage efficiency of the visa oil extract on cross-linking between the final glycated product and collagen ( in vitro )
콜라겐이 코팅된 96 웰 플레이트(well plate)에 서양고추냉이 과산화효소(Horseradish peroxidase)가 표지된 최종당화산물을 분주한 후 37℃에서 4시간 동안 인큐베이션(incubation)하여 콜라겐과 최종당화산물을 교차결합시켰다. 0.05% PBST에 3번 세척하여 콜라겐과 부착되지 않은 최종당화산물을 제거한 후, 최종당화산물 교차결합 절단제로 잘 알려진 ALT-711과 비자나무 유박 추출물을 37℃에서 16시간 처리하였다. 0.05% PBST에 3번 세척하고, TMB를 기질(substrate)로 하여 발색 한 후 450 nm에서 흡광도를 측정하였다. 콜라겐과 최종당화산물의 교차결합 정도는 하기 수학식 2와 같이 계산한다. 그 결과는 하기 표 2 및 도 1에 나타내었다.The final glycosylated product labeled with horseradish peroxidase was dispensed into a collagen-coated 96-well plate and incubated at 37 ° C for 4 hours to cross-link the collagen and the final glycosylation product . After washing with 0.05% PBST for 3 times to remove collagen and unattached end saccharification products, ALT-711 and Visa woodberry extracts, well known as the final saccharide cross-linking cleavage agent, were treated at 37 ° C for 16 hours. After washing 3 times with 0.05% PBST, TMB was developed as a substrate and absorbance was measured at 450 nm. The degree of cross-linking between the collagen and the final glycation product is calculated by the following equation (2). The results are shown in Table 2 and FIG.
도 1은 최종당화산물과 콜라겐의 교차결합에 대한 비자나무 유박 추출물의 절단 효능을 비교 평가한 결과를 나타낸 도면이다. FIG. 1 is a graph showing the results of comparative evaluation of the cleavage efficacy of a visa oil extract against cross-linking of collagen with a final glycation end product.
(mM)ALT-711
(mM)
(ppm)Visa tree extract
(ppm)
(ppm)Visa tree leaves extract
(ppm)
상기 표 2에 기재된 바와 같이, 비자나무 유박 추출물은 양성대조군으로 사용한 ALT-711보다 교차결합 절단 효능이 더 우수하게 나타남을 확인할 수 있다. 반면에 비자나무 추출물은 교차결합 절단 효능이 없었다.As shown in the above Table 2, it can be confirmed that the extract of Visa Extract has better cross-linking activity than ALT-711 used as a positive control. On the other hand, the visa tree extract had no cross-linking cleavage efficacy.
하기에 본 발명의 조성물을 이용한 화장료의 제제예를 예시한다.Formulation examples of cosmetic compositions using the composition of the present invention are illustrated below.
제제예 １ : 화장료 제제Formulation Example 1: Cosmetic preparation
1-1. 유연화장수1-1. Softening longevity
1-2. 영양화장수1-2. Nutritional lotion
1-3. 영양크림1-3. Nourishing cream
1-4. 마사지 크림1-4. Massage cream
1-5. 팩1-5. pack
제제예 ２ : 약학적 제제Formulation Example 2: Preparation of a pharmaceutical preparation
2-1. 산제의 제조2-1. Manufacture of Powder
상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조하였다.The above components were mixed and packed in airtight bags to prepare powders.
2-2. 정제의 제조2-2. Manufacture of tablets
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
2-3. 캡슐제의 제조2-3. Preparation of capsules
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.
Claims (6)
상기 질환이 비자나무 유박 추출물에 의한 최종당화산물 생성 억제 및 분해 촉진에 의해 예방 또는 치료되는 것임을 특징으로 하는 약학적 조성물.The method according to claim 1,
Wherein said disease is prevented or treated by inhibiting the formation of a final glycosylation product and accelerating decomposition by the extract of Vijayama japonica.
상기 피부 노화가 비자나무 유박 추출물에 의한 최종당화산물 생성 억제 및 분해 촉진에 의해 예방 또는 개선되는 것임을 특징으로 하는 화장료 조성물.The method of claim 3,
Wherein the aging of the skin is prevented or ameliorated by inhibiting the formation of the final glycation end product by the extract of Vijayami extract and accelerating the decomposition.
상기 질환 또는 피부 노화가 비자나무 유박 추출물에 의한 최종당화산물 생성 억제 및 분해 촉진에 의해 예방 또는 개선되는 것임을 특징으로 하는 식품 조성물.6. The method of claim 5,
Wherein said disease or skin aging is prevented or ameliorated by inhibition of the formation of final glycosylation products and promotion of degradation by the extract of Viaculaceae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170115269A KR101958454B1 (en) | 2017-09-08 | 2017-09-08 | Composition for blocking AGEs production and promoting AGEs decomposition comprising defatted Torreya nucifera's seed extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170115269A KR101958454B1 (en) | 2017-09-08 | 2017-09-08 | Composition for blocking AGEs production and promoting AGEs decomposition comprising defatted Torreya nucifera's seed extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101958454B1 true KR101958454B1 (en) | 2019-03-18 |
Family
ID=65949000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170115269A KR101958454B1 (en) | 2017-09-08 | 2017-09-08 | Composition for blocking AGEs production and promoting AGEs decomposition comprising defatted Torreya nucifera's seed extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101958454B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240062623A (en) | 2022-11-02 | 2024-05-09 | 주식회사 래디안 | Cosmetic compostion comprising phellodendron amurense extract for inhibiting skin glycation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050122074A (en) * | 2004-06-23 | 2005-12-28 | 주식회사 에스티씨나라 | Cosmetic composition comprising torreya nucifera extract as active ingredient for improving skin wrinkle and elasticity |
| KR20060043067A (en) * | 2004-03-03 | 2006-05-15 | 한국생명공학연구원 | Composition comprising extract of torreya nucifera or abietane diterpenoid compounds isolated from them for prevention and treatment of cardiovascular disease |
| KR20130134480A (en) * | 2012-05-31 | 2013-12-10 | (주)아모레퍼시픽 | Extract of torreya sp.treated enzyme |
-
2017
- 2017-09-08 KR KR1020170115269A patent/KR101958454B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060043067A (en) * | 2004-03-03 | 2006-05-15 | 한국생명공학연구원 | Composition comprising extract of torreya nucifera or abietane diterpenoid compounds isolated from them for prevention and treatment of cardiovascular disease |
| KR20050122074A (en) * | 2004-06-23 | 2005-12-28 | 주식회사 에스티씨나라 | Cosmetic composition comprising torreya nucifera extract as active ingredient for improving skin wrinkle and elasticity |
| KR20130134480A (en) * | 2012-05-31 | 2013-12-10 | (주)아모레퍼시픽 | Extract of torreya sp.treated enzyme |
Non-Patent Citations (1)
| Title |
|---|
| Journal of agricultural and food chemistry, 2003, 51(6), pp. 1586-1591* * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240062623A (en) | 2022-11-02 | 2024-05-09 | 주식회사 래디안 | Cosmetic compostion comprising phellodendron amurense extract for inhibiting skin glycation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101851625B1 (en) | Composition for improving skin wrinkle and enhancing elasticity | |
| KR101702056B1 (en) | Baby Aloe vera concentrate or extract having excellent effects of promotion of skin cell proliferation, antioxidant and anti-allergy | |
| KR100999870B1 (en) | Pharmaceutical composition for the prevention and treatment of allergic skin diseases containing extract of Houttuynia Cordata Thub and Ulmus davidana var.Japonica as an active ingredient | |
| KR101958454B1 (en) | Composition for blocking AGEs production and promoting AGEs decomposition comprising defatted Torreya nucifera's seed extract | |
| KR102014903B1 (en) | Composition for blocking AGEs production and promoting AGEs decomposition comprising Korthalsella japonica extracts | |
| KR102577528B1 (en) | Composition for improving skin | |
| KR20090107342A (en) | Pharmaceutical composition for the prevention and treatment of allergic skin diseases containing extract of Houttuynia Cordata, Centella asiatica, Plantago asiatica, Ulmus davidana var. Japonica and Morus alba L. as an active ingredient | |
| KR101695372B1 (en) | Composition for improving wrinkle and elasticity containing ribes nigrum extracts | |
| KR20220082974A (en) | A composition for stimulating growth of hairs contaning rhynchosia nulubilis complex extracts | |
| JP4261571B2 (en) | Collagen production promoter, skin cosmetics and cosmetics | |
| KR102655491B1 (en) | Compositions for Improving Skin Wrinkles Using an Extract of Spiraea chinensis | |
| KR102403354B1 (en) | Composition for strengthening skin barrier and moisturizing skin | |
| KR102563733B1 (en) | Composition for wound treatment or skin regeneration containing Aloe vera flower extract as active ingredients | |
| KR102561258B1 (en) | Composition for controlling sebum and improving pore comprising Jasminum Officinale, Salix Alba (willow) bark and Solanum melogena fruit extract | |
| KR102429214B1 (en) | A composition for stimulating growth of hairs contaning natural complex extracts | |
| KR102322974B1 (en) | Compositions for Improving Skin Wrinkles Using an Extract of Boehmeria tricuspis var. unicuspis | |
| KR102162843B1 (en) | Composition for preventing or treating skin disease comprising extract of Corylus heterophylla | |
| KR20180019847A (en) | Composition for Antiobesity Comprising Extract of Protaetia Orientalis Larva and Calamansi | |
| KR102247336B1 (en) | Compositions for Improving Skin Wrinkles and Anti-oxidative Composition Using an Extract of Boehmeria tricuspis | |
| KR102247331B1 (en) | Compositions for Improving Skin Wrinkles and Anti-oxidative Composition Using an Extract of Boehmeria tricuspis var. unicuspis | |
| JP5993724B2 (en) | Elastin production promoter and skin cosmetics | |
| JP4261572B2 (en) | Collagen production promoter, skin cosmetics and cosmetics | |
| KR101986008B1 (en) | Pharmaceutical composition for preventing or treating atopic dermatitis comprising extract of resveratrol-enriched rice or resveratrol enriched rice callus as an active ingredient | |
| KR20230157782A (en) | Compositions for preventing or improving skin damage comprising Zanthoxylum schinifolium oil as an active ingredient | |
| KR20240085594A (en) | Compositions for Improving Skin Wrinkles Using Chrysoeriol Isolated from Veratrum versicolor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |